Linked-evidence modelling of G6PD testing to guide radical cure of Plasmodium vivax
Viewed:
91
To eliminate vivax malaria, treatment is required that cures both the bloodstage infection and also kills any dormant parasites in the liver (called hypnozoites). This is called radical cure. Unfortunately, the standard doses of the 8-aminoquinoline drugs used for radical cure can cause severe haemolysis when given to patients who have glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common human enzyme polymorphism.
This project creates mathematical models informed by available evidence to investigate the impact on patient morbidity of using qualitative and semi-quantitative near-patient G6PD tests to guide treatment decisions, compared to providing radical cure with no G6PD testing.
Geographical area of data collection
text
Global
Publications
Gatton ML (2024) Linked-evidence modelling of qualitative G6PD testing to inform low- and intermediate-dose primaquine treatment for radical cure of Plasmodium vivax. PLoS Negl Trop Dis 18(9): e0012486.
http://dx.doi.org/10.1371/journal.pntd.0012486
Research areas
Mosquito-borne disease
Infectious diseases
Public
health
G6PD deficiency
G6PD test
Malaria
Mathematical modelling
Radical cure
Biostatistics
Diagnostics
Plasmodium vivax
Related information
Centre for Immunology and Infection Control, QUT
https://research.qut.edu.au/ciic/
Partner institution
World Health Organization (WHO)
https://www.who.int/
Connections
Has association with
Has chief investigator
Contacts
Name: Professor Michelle Gatton
Email: m.gatton@qut.edu.au
Other
Date record created:
2024-06-22T10:38:19
Date record modified:
2024-09-06T11:44:51
Record status:
Published - Open Access